# The Efficacy and Safety of Pegylated Liposomal Doxorubicin Compared With Capecitabine as First Line Chemotherapy for Metastatic Breast Cancer (P04445/MK-2746-071)

> **NCT00266799** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 210 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Pegylated liposomal doxorubicin (SCH 200746)
- **DRUG:** Capecitabine

## Key facts

- **NCT ID:** NCT00266799
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-01-13
- **Primary completion:** 2010-09-29
- **Final completion:** 2010-10-18
- **Target enrollment:** 210 (ACTUAL)
- **Last updated:** 2017-06-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00266799

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00266799, "The Efficacy and Safety of Pegylated Liposomal Doxorubicin Compared With Capecitabine as First Line Chemotherapy for Metastatic Breast Cancer (P04445/MK-2746-071)". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00266799. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*